Loading organizations...

§ Private Profile · Boston, MA, USA
We use AI to design antibodies for intractable diseases
Nabla Bio has raised $37.0M across 2 funding rounds.
Key people at Nabla Bio.
Nabla Bio was founded in 2020 by Frances Anastassacos (Founder) and Surge Biswas (Founder).
Nabla Bio has raised $37.0M in total across 2 funding rounds.
Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University.
Nabla Bio has raised $37.0M across 2 funding rounds. Most recently, it raised $26.0M Series A in May 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2024 | $26M Series A | Radical Ventures | Amplify Partners, Felicis Ventures, Adam D'angelo, Yann Lecun | Announced |
| Dec 1, 2021 | $11M Seed | Zetta Venture Partners, Alex Morgan | BMW I Ventures, Menlo Ventures, Cantos, Fifty Years | Announced |
Nabla Bio is a U.S.-based biotechnology company that uses advanced artificial intelligence (AI) to design *de novo* antibodies targeting intractable diseases, including hard-to-drug membrane proteins like G protein-coupled receptors (GPCRs). Their proprietary AI platform, called Joint Atomic Model (JAM), generates entirely new antibody sequences optimized for affinity, manufacturability, and drug-like properties, enabling a rapid design-to-experiment feedback loop of just three to four weeks—the fastest in the industry. Nabla serves pharmaceutical partners and aims to accelerate therapeutic development by overcoming traditional antibody discovery limitations, focusing on diseases with high unmet medical need. The company has demonstrated strong growth momentum, securing multi-million dollar partnerships, notably a second major collaboration with Takeda Pharmaceutical potentially worth over $1 billion in success-based payments[1][2][3].
Nabla Bio was co-founded in 2020 by Surge Biswas, PhD, and Anastassacos, who brought together expertise in AI, protein design, and biotechnology. The idea emerged from deep scientific discussions and a shared vision to transform drug development from a trial-and-error process into a design-driven discipline. Early traction came quickly with $11 million in seed funding from prominent investors like Khosla Ventures and Zetta Venture Partners in 2021. The company’s breakthrough was the development of JAM, an AI system trained on massive protein sequence and structure data combined with proprietary human-relevant biological measurements, enabling the rapid generation and validation of antibody candidates[3][6].
Nabla Bio rides the wave of AI-driven innovation in biopharmaceutical R&D, a sector increasingly focused on leveraging computational methods to accelerate drug discovery. The timing is critical as traditional antibody discovery methods are slow, costly, and limited in scope, especially for complex targets like GPCRs. Market forces favor scalable, AI-powered platforms that can generate novel biologics with precision and speed, addressing unmet medical needs in oncology, immunology, and beyond. Nabla’s approach exemplifies the shift from empirical screening to rational design, influencing the broader ecosystem by demonstrating that AI can produce therapeutic-grade antibodies rapidly and reliably, potentially reshaping how biologics are discovered and developed[1][3][7].
Looking ahead, Nabla Bio is poised to expand its platform capabilities to more challenging targets such as ion channels and to develop antibodies recognizing specific receptor conformations, further enhancing therapeutic precision. The company’s success will likely be shaped by ongoing advances in AI, integration of patient-relevant biological data, and deepening partnerships with pharmaceutical companies. As AI models improve and hit rates increase, Nabla could lead a paradigm shift in biologics discovery, moving the industry toward fully design-driven drug development. Their continued innovation and validation in clinical settings will be key to cementing their influence in the biotech landscape and delivering new treatments for diseases previously considered intractable[5][6].
Nabla Bio was founded in 2020 by Frances Anastassacos (Founder) and Surge Biswas (Founder).
Nabla Bio has raised $37.0M in total across 2 funding rounds.
Nabla Bio's investors include Radical Ventures, Amplify Partners, Felicis Ventures, Adam D'Angelo, Yann LeCun, Zetta Venture Partners, Alex Morgan, BMW i Ventures, Menlo Ventures, Cantos, Fifty Years.
Key people at Nabla Bio.